Meredith Yeager, PhD, Scientific Director
Email:
yeagerm@mail.nih.gov
Telephone: (301) 435-7613
CGF web site: http://cgf.nci.nih.gov
Mission: The aim of the Core Genotyping
Facility (CGF) is to meet the genotyping and DNA sequencing needs
of the NCI’s Division of Cancer Epidemiology and Genetics (DCEG)
and Center for Cancer Research (CCR). The facility performs high-throughput
genotyping and sequencing to support genetic analysis for a broad
range of projects for the intramural research program of the NCI.
Expertise: CGF assists NCI investigators with technical advice
and consultation in several areas:
- Bioinformatics support and consulting
- Genotype assay design
- High-throughput genotyping
- Data cleaning
- Data analysis
Activities: The CGF is assessing human genetic variations,
including Single Nucleotide Polymorphisms (SNPs) and other types of
variations, including microsatellites, insertion/deletion mutations,
variable nucleotide tandem repeats (VNTRs), using four major platforms:
- TaqMan™ Fluorescent 5’ Nuclease cleavage
- Primer Extension detected by Matrix Assisted Laser Deionization/Adsorption
- Time of Flight (MALDI-TOF) or SNaPShot™ fluorescent nucleotide
extension
- Fluorescent DNA fragment analysis and
sequencing detected by automated capillary electrophoresis systems
- MGB Eclipse™ 3’ Hybridization
Triggered Fluorescence Genotype assay design
- All assays are developed and validated in conjunction with the
SNP500Cancer project, http://snp500cancer.nci.nih.gov.
The goal of the SNP500Cancer project, a Cancer Genome Anatomy Project
(CGAP) resource, is to resequence 102 reference samples to find known
or newly discovered single nucleotide polymorphisms (SNPs) which are
of immediate importance to molecular epidemiology studies in cancer.
New Technologies: The CGF evaluates and develops
technologies for cancer genomic research. Current technologies being evaluated:
- Development of a Laboratory
Information Management System (LIMS) to support the CGF.
- Evaluation of molecular
genetic technologies (quantification of DNA, whole genome amplification).
- Evaluation of genotyping
technologies for possible introduction into the CGF’s laboratory
(allelotyping, SNP linkage panels).
